3.96
price up icon0.25%   0.010
pre-market  Vorhandelsmarkt:  3.95   -0.010   -0.25%
loading
Schlusskurs vom Vortag:
$3.95
Offen:
$3.95
24-Stunden-Volumen:
1.99M
Relative Volume:
1.11
Marktkapitalisierung:
$255.66M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-71.17M
KGV:
-2.8489
EPS:
-1.39
Netto-Cashflow:
$-70.97M
1W Leistung:
+178.87%
1M Leistung:
+284.47%
6M Leistung:
+40.93%
1J Leistung:
-15.38%
1-Tages-Spanne:
Value
$3.95
$3.96
1-Wochen-Bereich:
Value
$3.94
$3.99
52-Wochen-Spanne:
Value
$0.721
$6.24

Inozyme Pharma Inc Stock (INZY) Company Profile

Name
Firmenname
Inozyme Pharma Inc
Name
Telefon
857-330-4340
Name
Adresse
321 SUMMER STREET, BOSTON
Name
Mitarbeiter
67
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
INZY's Discussions on Twitter

Vergleichen Sie INZY mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
INZY
Inozyme Pharma Inc
3.96 91.68M 0 -71.17M -70.97M -1.39
Biotechnology icon
ONC
Beigene Ltd Adr
238.76 24.41B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
434.03 111.55B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.2548 42.47M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
596.85 63.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
72.69 5.92B 0 -153.72M -103.81M -2.00

Inozyme Pharma Inc Stock (INZY) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-12 Eingeleitet Raymond James Outperform
2024-09-12 Eingeleitet Stifel Buy
2024-08-13 Fortgesetzt Jefferies Buy
2024-05-30 Eingeleitet Wells Fargo Overweight
2023-03-23 Hochstufung Jefferies Hold → Buy
2022-05-26 Eingeleitet Jefferies Hold
2022-02-07 Eingeleitet H.C. Wainwright Buy
2021-11-29 Eingeleitet Needham Buy
2020-08-18 Eingeleitet BofA Securities Buy
2020-08-18 Eingeleitet Cowen Outperform
2020-08-18 Eingeleitet Piper Sandler Overweight
2020-08-18 Eingeleitet Wedbush Outperform
Alle ansehen

Inozyme Pharma Inc Aktie (INZY) Neueste Nachrichten

pulisher
May 22, 2025

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More - Zacks Investment Research

May 22, 2025
pulisher
May 22, 2025

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz - MSN

May 22, 2025
pulisher
May 21, 2025

BioMarin’s Acquisition of Inozyme Pharma - Global Legal Chronicle

May 21, 2025
pulisher
May 21, 2025

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc.INZY - Business Wire

May 21, 2025
pulisher
May 21, 2025

BioMarin agrees to acquire Inozyme for $270m - MSN

May 21, 2025
pulisher
May 20, 2025

Biotech Alert: Searches spiking for these stocks today - Yahoo Finance

May 20, 2025
pulisher
May 19, 2025

Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens - MSN

May 19, 2025
pulisher
May 19, 2025

BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition - MSN

May 19, 2025
pulisher
May 19, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

May 19, 2025
pulisher
May 19, 2025

Inozyme Pharma finds buyer in BioMarin after strategic review - The Business Journals

May 19, 2025
pulisher
May 19, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq – INZY), TXNM Energy, Inc. (NYSETXNM), Servotronics, Inc. (NYSE AmericanSVT), Protagenic Therapeutics, Inc. (Nasdaq – - TradingView

May 19, 2025
pulisher
May 19, 2025

BioMarin: Inozyme Acquisition Falls Short Of Offsetting Looming Revenue Risks (Downgrade) - Seeking Alpha

May 19, 2025
pulisher
May 19, 2025

Piper Sandler Downgrades Inozyme Pharma to Neutral From Overweight, Lowers Price Target to $4 From $23 - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

TD Cowen Downgrades Inozyme Pharma to Hold From Buy, Price Target is $4 - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

Raymond James Downgrades Inozyme Pharma to Market Perform From Outperform - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

BioMarin to acquire Inozyme to enhance its enzyme therapy portfolio - World Pharmaceutical Frontiers

May 19, 2025
pulisher
May 18, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, NVEE, CHTR, INZY on Behalf of Shareholders - GlobeNewswire Inc.

May 18, 2025
pulisher
May 18, 2025

BioMarin Buying Inozyme Pharma In $270 Million Deal - Pulse 2.0

May 18, 2025
pulisher
May 18, 2025

StockWatch: With Inozyme Buyout, BioMarin Pursues Growth via M&A - Genetic Engineering and Biotechnology News

May 18, 2025
pulisher
May 18, 2025

The week in pharma: action, reaction and insight – week to May 16 - The Pharma Letter

May 18, 2025
pulisher
May 18, 2025

Wells Fargo & Company Reaffirms Equal Weight Rating for Inozyme Pharma (NASDAQ:INZY) - Defense World

May 18, 2025
pulisher
May 18, 2025

Inozyme Pharma (NASDAQ:INZY) Stock Rating Lowered by Wedbush - Defense World

May 18, 2025
pulisher
May 18, 2025

Inozyme Pharma (NASDAQ:INZY) Earns Hold Rating from Jefferies Financial Group - Defense World

May 18, 2025
pulisher
May 17, 2025

BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal - MSN

May 17, 2025
pulisher
May 17, 2025

Leerink bullish on BioMarin following Inozyme deal, expects additional BD - Yahoo Finance

May 17, 2025
pulisher
May 17, 2025

Wedbush Has Negative Outlook for Inozyme Pharma Q2 Earnings - Defense World

May 17, 2025
pulisher
May 16, 2025

Inozyme Pharma (INZY) Downgraded by Needham Analyst | INZY Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Inozyme downgraded to Hold from Buy at TD Cowen - TipRanks

May 16, 2025
pulisher
May 16, 2025

BioMarin to acquire Inozyme for $270 million By Investing.com - Investing.com South Africa

May 16, 2025
pulisher
May 16, 2025

Inozyme Pharma (INZY) Downgraded by Wells Fargo | INZY Stock New - GuruFocus

May 16, 2025
pulisher
May 16, 2025

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business - insights.citeline.com

May 16, 2025
pulisher
May 16, 2025

Inozyme Pharma (INZY) Downgraded by Wells Fargo | INZY Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Inozyme stock rating cut to Hold at Jefferies, target to $4 from $15 - Investing.com Nigeria

May 16, 2025
pulisher
May 16, 2025

Inozyme stock rating cut to Hold at Jefferies, target to $4 from $15 By Investing.com - Investing.com South Africa

May 16, 2025
pulisher
May 16, 2025

Inozyme (INZY) Downgraded Following Acquisition Deal | INZY Stoc - GuruFocus

May 16, 2025
pulisher
May 16, 2025

TD Cowen cuts Inozyme stock rating post-acquisition news - Investing.com Australia

May 16, 2025
pulisher
May 16, 2025

TD Cowen cuts Inozyme stock rating post-acquisition news By Investing.com - Investing.com Nigeria

May 16, 2025
pulisher
May 16, 2025

Biomarin snags potential ‘first-in-disease’ ERT in $270M Inozyme buy - BioWorld MedTech

May 16, 2025
pulisher
May 16, 2025

BioMarin’s $270M Inozyme Acquisition Brings Drug That Could Become First for a Rare Disease - MedCity News

May 16, 2025
pulisher
May 16, 2025

Inozyme Pharma (INZY) Sees Price Target Slash and Downgrade by J - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Inozyme Pharma’s Strategic Acquisition by Biomarin: Analyst Holds Rating Amid Favorable Shareholder Outcome and Strategic Alignment - TipRanks

May 16, 2025
pulisher
May 16, 2025

Inozyme (INZY) Downgraded Following Acquisition by BioMarin | INZY Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Dollar Stock Skyrockets 179% On BioMarin Takeover - Investor's Business Daily

May 16, 2025
pulisher
May 16, 2025

BioMarin stock rises following Inozyme Pharma acquisition By Investing.com - Investing.com Nigeria

May 16, 2025
pulisher
May 16, 2025

BioMarin stock rises following Inozyme Pharma acquisition - Investing.com Australia

May 16, 2025
pulisher
May 16, 2025

BioMarin to acquire Inozyme for $4.00 per share in cash, or $270M - TipRanks

May 16, 2025
pulisher
May 16, 2025

Jefferies Downgrades Inozyme Pharma to Neutral From Buy - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

BioMarin Pharmaceutical: Balancing Opportunities and Risks Amid Inozyme Acquisition and Market Challenges - TipRanks

May 16, 2025
pulisher
May 16, 2025

Jefferies Downgrades Inozyme (INZY) After Acquisition Announceme - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Jefferies Downgrades Inozyme (INZY) After Acquisition Announcement | INZY Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Inozyme downgraded to Hold from Buy at Jefferies - TipRanks

May 16, 2025

Finanzdaten der Inozyme Pharma Inc-Aktie (INZY)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$581.44
price down icon 0.60%
$1.39
price up icon 6.92%
$32.50
price down icon 0.28%
$289.00
price down icon 1.22%
$4.2299
price up icon 5.48%
$72.69
price down icon 1.89%
Kapitalisierung:     |  Volumen (24h):